```
File 410:The Chronolog 1991-2010/ Dec
       (c) 2011 Dialog.

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
?
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
? 5,73,155,399
>>>Unrecognizable Command
? begin 5,73,155,399
       03mar11 16:31:55 User208760 Session D3249.2
            $0.00     0.230 DialUnits File410
     $0.00  Estimated cost File410
     $2.42  TELNET
     $2.42  Estimated cost this search
     $3.03  Estimated total session cost   0.382 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R) 1926-2011/Feb W4
         (c) 2011 The Thomson Corporation
  File  73:EMBASE 1974-2011/Mar 03
         (c) 2011 Elsevier B.V.
  File 155:MEDLINE(R) 1950-2011/Mar 02
         (c) format only 2011 Dialog
*File 155: Medline has been reloaded with the 2011 MeSH
thesaurus.
  File 399:CA SEARCH(R) 1967-2010/UD=15410
         (c) 2011 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

      Set  Items  Description
      ---  -----  -----------
? s (bb5(w)1)(20n)(antibod?)(20n)(c5?)
Processing
             102  BB5
        16082561  1
         2800427  ANTIBOD?
          419827  C5?
      S1      19  (BB5(W)1)(20N)(ANTIBOD?)(20N)(C5?)
? rd s1
      S2       9  RD S1  (unique items)
? s s2 and (conversion or convertase)
               9  S2
          521150  CONVERSION
           13311  CONVERTASE
      S3       1  S2 AND (CONVERSION OR CONVERTASE)
? t s3/7/all

 3/7/1     (Item 1 from file: 73)
DIALOG(R)File  73:EMBASE
(c) 2011 Elsevier B.V. All rts. reserv.

0080685483     EMBASE/Medline No: 2005329801
  Strategies of therapeutic complement inhibition
  ISSUE TITLE: 10th Meeting on Complement in Human Disease
  Mollnes T.E.; Kirschfink M.
```

Institute of Immunology, Rikshospitalet University Hospital, University of Oslo, N-0027 Oslo, Norway
AUTHOR EMAIL: t.e.mollnes@labmed.uio.no
CORRESP. AUTHOR/AFFIL: Mollnes T.E.: Institute of Immunology, Rikshospitalet University Hospital, University of Oslo, N-0027 Oslo, Norway
CORRESP. AUTHOR EMAIL: t.e.mollnes@labmed.uio.no

Molecular Immunology (Mol. Immunol.) (United Kingdom) January 1, 2006 , 43/1-2 (107-121)
CODEN: IMCHA ISSN: 0161-5890
PUBLISHER ITEM IDENTIFIER: S0161589005002075
DOI: 10.1016/j.molimm.2005.06.014
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 184

The involvement of complement in the pathogenesis of a great number of partly life threatening diseases defines the importance to develop inhibitors which specifically interfere with its deleterious action. Endogenous soluble complement-inhibitors, antibodies or low molecular weight antagonists, either blocking key proteins of the cascade reaction or neutralizing the action of the complement-derived anaphylatoxins have successfully been tested in various animal models over the past years. Promising results consequently led to first clinical trials. This review is focused on different approaches for the development of inhibitors, on their site of action in the cascade, on possible indications for complement inhibition based on experimental animal data, and on potential side effects of such treatment. (c) 2005 Elsevier Ltd. All rights reserved.

DRUG DESCRIPTORS:
...agent--drug therapy--dt; aprotinin; CD59 antigen--drug therapy--dt; classical complement pathway C3 C5 convertase--endogenous compound --ec; complement component C1s inhibitor--drug therapy--dt; complement component C5 inhibitor--clinical...
MEDICAL DESCRIPTORS:
DRUG TERMS (UNCONTROLLED): apt 070--drug therapy--dt; complement component c5 antibody--drug therapy--dt; complement component c5 antibody--pharmacology--pd; complement component c5a antibody--pharmacology--pd; complement component c8 antibody --pharmacology--pd; complement receptor 1 related protein--drug therapy--dt ; complement receptor 1 related protein--pharmacology--pd; monoclonal
antibody ***bb5*** . ***1*** --drug therapy--dt; monoclonal
antibody ***bb5*** . ***1*** --pharmacology--pd; recombinant complement
component C3b receptor--drug comparison--cm; recombinant complement component C3b receptor...
...CAS REGISTRY NO.: 9087-70-1 (aprotinin); 56626-15-4 (classical
complement pathway C3 C5 ***convertase***); 80295-37-0...
?